-+ 0.00%
-+ 0.00%
-+ 0.00%

Integra Lifesciences Affirms FY2026 Adj EPS Guidance of $2.30-$2.40 vs $2.42 Est; Affirms FY2026 Sales Guidance of $1.634B-$1.654B vs $1.661B Est

Benzinga·10/21/2026 10:01:50
Listen to the news
Integra Lifesciences (NASDAQ:IART) affirms FY2026 Adj EPS guidance from $2.30-$2.40 to $2.30-$2.40 vs $2.42 analyst estimate. Affirms FY2026 sales outlook from $1.634 billion-$1.654 billion to $1.634 billion-$1.654 billion vs $1.661 billion estimate.